Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist / 임상당뇨병
Journal of Korean Diabetes
;
: 149-156, 2019.
Artículo
en Coreano
| WPRIM
| ID: wpr-761490
ABSTRACT
According to the American Diabetes Association (ADA) and the European Association for the Study of Diabetes guideline for treatment of diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) is recommended in diabetic patients with established atherosclerotic cardiovascular disease. This recommendation is based on the results of recent cardiovascular outcome trials of this kind of medications. GLP-1 RAs have a glucose lowering effect with weight loss and a lower incidence of hypoglycemia, and can improve cardiovascular outcomes such as three-point major cardiovascular events composed of death from cardiovascular causes, non-fatal myocardial infarction, and non-fatal stroke. Also, several GLP-1 RAs have beneficial effects on renal outcomes, mainly due to improvement in macroalbuminuria. In addition, high-dose liraglutide (3 mg/day subcutaneous injection) showed efficacy for reducing body weight. Therefore GLP-1 RA may be effective in patients with established cardiovascular disease, chronic kidney disease, and/or metabolic syndrome.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Peso Corporal
/
Enfermedades Cardiovasculares
/
Pérdida de Peso
/
Incidencia
/
Accidente Cerebrovascular
/
Diabetes Mellitus
/
Insuficiencia Renal Crónica
/
Péptido 1 Similar al Glucagón
/
Liraglutida
/
Receptor del Péptido 1 Similar al Glucagón
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio de incidencia
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Coreano
Revista:
Journal of Korean Diabetes
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS